ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Clinical utility of thiopurine metabolite levels in monitoring patients with inflammatory bowel disease: A single-centre retrospective study.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic drug monitoring (TDM) of thiopurines is crucial for optimizing inflammatory bowel disease (IBD) treatment. Despite its benefits, data on thiopurine levels in Indian IBD patients is limited. Thus, we assessed 6-thioguanine nucleotide (6-TGN) and 6-methyl mercaptopurine (6-MMP) levels in patients on thiopurine therapy and evaluated their correlation with dosage and clinical outcome.
methods6-TGN and 6-MMP levels in IBD patients (2016-2024) were measured using an in-house high-pressure liquid chromatography (HPLC) method. Levels were then correlated with clinical data, disease activity and genotyping to assess the impact of metabolite monitoring on clinical outcomes and therapy management.
resultsOf the 638 samples evaluated from 418 IBD patients, 6-TGN levels were sub-therapeutic in 323, therapeutic in 163 and supra-therapeutic in 99. A majority (~ 90%) of patients on 1-2 mg/kg and > 2 mg/kg doses achieved therapeutic levels than those on < 1 mg/kg, though no correlation with disease activity was found. Repeat monitoring in 132 patients led to dose adjustments in 71 due to toxicity, low 6-TGN, disease control or shunting. Genotyping was done in 130 patients. Thiopurine toxicity caused discontinuation in 34 patients (11%), with nine cases linked to thiopurine methyltransferase/nucleoside diphosphate-linked moiety X-type motif 15 (TPMT/NUDT15) variants.
conclusionOnly one-third of patients on thiopurine therapy reached therapeutic levels and 6-TGN levels did not correlate with remission. Most patients had sub-therapeutic 6-TGN levels, resulting in poor disease control despite on recommended doses. Literature-defined 6-TGN targets may be insufficient for Indian IBD patients. Larger studies are needed to determine the optimal 6-TGN target and therapeutic threshold for remission in our population.
Indexed as
Identifiers
40682730What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.